Moderna ( ($MRNA) ) has risen by 17.64%. Read on to learn why. Moderna’s stock has seen a significant rise of 17.64% over the past week, capturing ...

A mobile research unit will be travelling to some of the remotest parts of Cornwall as part of the trial to find a vaccine for the winter ...

The Florida surgeon general in January called for a halt in the use of covid mRNA vaccines. And in Texas, Attorney General ...

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) saw unusually large options trading activity on Thursday. Stock investors purchased 143,752 call options on the company. This represents an increase of ...

Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open ...

Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s ...

Moderna, AbbVie, and Danaher are the three Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares in companies that focus on developing and ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech ...

The leader of an iconic apparel company and the co-founder and chair of Moderna are the honored speakers for the Worcester ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

Moderna, Inc. (NASDAQ:MRNA) shares rose for a second day on Wednesday, adding 15.94 percent to finish at $35.21 apiece as ...